Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

3 Oct 2020

Abstract excerpt

Replication-incompetent adenoviral vectors have been under investigation as a platform to carry a variety of transgenes, and express them as a basis for vaccine development. A replication-incompetent adenoviral vector based on human adenovirus type 26 (Ad26) has been evaluated in several clinical trials. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infections and Outbreaks Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33676782
DOI: 10.1016/j.vaccine.2020.09.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessmentPMID 33676782Read ↗

Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessmentSemantic proximity Read ↗

The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platformSemantic proximity Read ↗

Human adenovirus type 26 basic biology and its usage as vaccine vectorSemantic proximity Read ↗

Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2Semantic proximity Read ↗

Adenoviruses as gene/vaccine delivery vectors: promises and pitfallsSemantic proximity Read ↗

Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral VectorsSemantic proximity Read ↗

The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 VaccineSemantic proximity Read ↗

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)Semantic proximity Read ↗

Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive ReviewSemantic proximity Read ↗

Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunitySemantic proximity Read ↗

Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectorsSemantic proximity Read ↗

Immunogenicity and efficacy of Ad26. COV2 .S: An adenoviral vector–based COVID ‐19 vaccineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.